Articles
Volume 6 Supplement 2
Current and new antitumor necrosis factor agents in perspective
- Reviews
- Edited by Peter E Lipsky and Ravinder N Maini
- Supported by an educational grant from Centocor, Inc.
|
Review
Current and new antitumor necrosis factor agents in perspective Ravinder N Maini Arthritis Res Ther 2004, 6(Suppl 2):S1-S2 (21 June 2004) |
|
Review
Does safety make a difference in selecting the right TNF antagonist? Roy Fleischmann, David Yocum Arthritis Res Ther 2004, 6(Suppl 2):S12-S18 (21 June 2004) |
|
Review
Does route of administration affect the outcome of TNF antagonist therapy? Sergio Schwartzman, G James Morgan Arthritis Res Ther 2004, 6(Suppl 2):S19-S23 (21 June 2004) |
|
Review
Effective use of TNF antagonists David Yocum Arthritis Res Ther 2004, 6(Suppl 2):S24-S30 (21 June 2004) |
|
Review
Ravinder N Maini Arthritis Res Ther 2004, 6(Suppl 2):S44 (21 June 2004) |
|
Review
Expanding the armamentarium for the spondyloarthropathies Paul M Peloso, Jürgen Braun Arthritis Res Ther 2004, 6(Suppl 2):S36-S43 (21 June 2004) |
|
Review
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Sergio Schwartzman, Roy Fleischmann, G James Morgan Arthritis Res Ther 2004, 6(Suppl 2):S3-S11 (21 June 2004) |
|
Review
Treating psoriatic arthritis: how effective are TNF antagonists? Alice B Gottlieb, Christian E Antoni Arthritis Res Ther 2004, 6(Suppl 2):S31-S35 (21 June 2004) |
